The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Anifrolumab Promising for SLE

Anifrolumab Promising for SLE

December 13, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ATLANTA—Anifrolumab is a fully human monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor. It blocks all type I interferon activity, including IFN-α, IFN-β and IFN-ω, which are cytokines that activate immune cells and upregulate antigen presentation. Between 60% and 80% of adults with systemic lupus erythematosus (SLE) have upregulation of type I interferon, which can serve as a biomarker for disease activity.

You Might Also Like
  • New SLE Drug May Allow Patients to Reduce Steroid Use
  • Zilretta Promising for Blood Glucose Levels; Plus Filgotinib Promising for RA
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
Explore This Issue
February 2020, January 2020
Also By This Author
  • Belimumab Promising for Children with Lupus Nephritis

TULIP-1 (Treatment of Uncontrolled Lupus via the Interferon Pathway), a phase 3 randomized, double-blind, placebo-controlled clinical trial (NCT02446912) evaluated the efficacy and safety of anifrolumab in patients with moderate to severe SLE. The results of the study were presented during the 2019 ACR/ARP Annual Meeting in November.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

To participate in the study, SLE patients had to meet ACR criteria, with an SLE Disease Activity Index 2000 (SLEDAI-2K) of 6 or more and a British Isles Lupus Assessment Group (BILAG) score of at least 1A or 2B. Patients were randomized to receive 300 mg of intravenous (IV) anifrolumab, 150 mg of IV anifrolumab or placebo every four weeks. Additionally, patients continued their standard therapy, which was required to remain at a stable dosing regimen throughout the study. The only deviation allowed from standard-of-care therapy was steroid tapering for patients receiving 10 mg or more of prednisone or an equivalent.

The study’s primary end point was the difference in the SLE responder index between anifrolumab and placebo-treated patients after one year of therapy. The study also assessed numerous secondary endpoints, including safety.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Results
All 457 randomized patients received at least one dose of the study drug and were included in the analyses. In total, 180 patients received 300 mg of anifrolumab, 93 patients received 150 mg of anifrolumab and 184 patients received placebo. The baseline characteristics and completion rates were similar across the treatment groups.

At Week 52, no difference in the SLE responder index rates existed between 300 mg anifrolumab-treated patients (36%; 65/180) and placebo-treated patients (40%; 74/184). The differences from baseline in secondary endpoints favored 300 mg anifrolumab-treated patients compared with placebo-treated patients. One secondary endpoint was the reduction of oral corticosteroid dosage, which was 48.8% for 300 mg anifrolumab-treated patients vs. 32.1% for placebo-treated patients, a difference of 16.7% (95% CI: 3.5, 29.8).

Serious adverse events occurred in 10.8% of 150 mg anifrolumab-treated patients and 13.9% of 300 mg anifrolumab-treated patients compared with 16.3% of placebo-treated patients. Herpes zoster occurred in 5% of patients treated with anifrolumab compared with 1.6% of placebo-treated patients.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Issue: February 2020, January 2020

You Might Also Like:
  • New SLE Drug May Allow Patients to Reduce Steroid Use
  • Zilretta Promising for Blood Glucose Levels; Plus Filgotinib Promising for RA
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
  • Effectiveness of Novel Therapies for Cutaneous SLE Explored

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)